JP Morgan Chase (JPM) Closes 2.25% Up on the Day for January 26

Equities Staff |

Dow Jones component JP Morgan Chase (JPM) saw its stock move 2.25% to $56.91, representing a per-share move of $1.25, on volume of 12.1 million shares for Tuesday.

JP Morgan Chase currently has a total float of 3.68 billion shares and moves 20.2 million a day, on average. The stock opened at $55.85 on January 26 and traded between a low of $55.81 and a high of $57.15. The stock now has a 50-day SMA of $63.77 and 200-day SMA of $64.13, and it has a high of $70.61 and low of $50.07 over the last year. Its P/E ratio is 9.3 and its P/B ratio is 0.95.

JPMorgan Chase & Co is a financial services firm and a banking institution. its segments are Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Management.

Based out of New York, NY, JP Morgan Chase has 235,678 employees and is helmed by CEO Douglas B. Petno / Mary Callahan Erdoes / Gordon A. Smith / James S. Dimon / Daniel Pinto.

For a deeper dive into the fundamentals of JP Morgan Chase, check out’s E.V.A. report for JPM.


The Dow Jones Industrial Average is the oldest and most-often cited stock market index for the American equities market. While it’s arguably outdated and inefficient, it remains the most visible representation of the stock market to the outside world. Consisting of 30 companies selected by the editorial board of the Wall Street Journal, it’s meant to give an overview of stock performances by looking at a slice of those mega- and large-cap companies deemed to best represent the broad economy.

The history of the index dates all the way back to 1896 when it was first created by Charles Dow, the legendary founding editor of the Wall Street Journal and founder of Dow Jones & Company, and Edward Jones, a statistician. The price-weighted, scaled index has since become a standard part of most major daily news recaps and has seen dozens of different companies pass through its ranks, with only General Electric (GE) remaining on the index since its inception.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…


Airbnb is a community marketplace for people to list, discover, and book unique accommodations around the world — online or from a mobile phone. Whether an apartment for a night,…